1. Home
  2. VIGL vs EHGO Comparison

VIGL vs EHGO Comparison

Compare VIGL & EHGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIGL
  • EHGO
  • Stock Information
  • Founded
  • VIGL 2020
  • EHGO 2015
  • Country
  • VIGL United States
  • EHGO China
  • Employees
  • VIGL N/A
  • EHGO N/A
  • Industry
  • VIGL Biotechnology: Pharmaceutical Preparations
  • EHGO
  • Sector
  • VIGL Health Care
  • EHGO
  • Exchange
  • VIGL Nasdaq
  • EHGO NYSE
  • Market Cap
  • VIGL 89.3M
  • EHGO 90.4M
  • IPO Year
  • VIGL 2022
  • EHGO 2024
  • Fundamental
  • Price
  • VIGL $2.64
  • EHGO $1.08
  • Analyst Decision
  • VIGL Strong Buy
  • EHGO
  • Analyst Count
  • VIGL 5
  • EHGO 0
  • Target Price
  • VIGL $21.00
  • EHGO N/A
  • AVG Volume (30 Days)
  • VIGL 2.6M
  • EHGO 556.8K
  • Earning Date
  • VIGL 03-25-2025
  • EHGO 02-19-2025
  • Dividend Yield
  • VIGL N/A
  • EHGO N/A
  • EPS Growth
  • VIGL N/A
  • EHGO N/A
  • EPS
  • VIGL N/A
  • EHGO 0.00
  • Revenue
  • VIGL N/A
  • EHGO $16,963,957.00
  • Revenue This Year
  • VIGL N/A
  • EHGO N/A
  • Revenue Next Year
  • VIGL N/A
  • EHGO N/A
  • P/E Ratio
  • VIGL N/A
  • EHGO $2,933.26
  • Revenue Growth
  • VIGL N/A
  • EHGO N/A
  • 52 Week Low
  • VIGL $1.49
  • EHGO $0.91
  • 52 Week High
  • VIGL $6.06
  • EHGO $5.50
  • Technical
  • Relative Strength Index (RSI)
  • VIGL 71.47
  • EHGO N/A
  • Support Level
  • VIGL $2.22
  • EHGO N/A
  • Resistance Level
  • VIGL $2.53
  • EHGO N/A
  • Average True Range (ATR)
  • VIGL 0.29
  • EHGO 0.00
  • MACD
  • VIGL 0.08
  • EHGO 0.00
  • Stochastic Oscillator
  • VIGL 80.47
  • EHGO 0.00

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

About EHGO ESHALLGO INC

Eshallgo Inc. focuses on two distinct market sectors: office supply sale and leasing, and after-sale maintenance and repair. It is an authorized distributor of brands of office equipment, including HP, Epson, Xerox, Sharp, Toshiba, Konica, Kyocera, and other brands.

Share on Social Networks: